Detalhe da pesquisa
1.
Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation.
Oncology
; 102(4): 291-298, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820607
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
3.
Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations.
Hepatol Res
; 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38801372
4.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
5.
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
J Gastroenterol Hepatol
; 39(6): 1164-1171, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38403468
6.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602340
7.
Changes in characteristics of gastroenterology center inpatients in Japan because of rapidly aging society.
J Gastroenterol Hepatol
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634347
8.
Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria.
Oncology
; 101(9): 575-583, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459848
9.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552968
10.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455517
11.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307798
12.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657420
13.
Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test.
Hepatol Res
; 53(1): 43-50, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063444
14.
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Hepatol Res
; 53(2): 116-126, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36316794
15.
Clinical role of radiofrequency ablation for early-stage hepatocellular carcinoma in an advanced aging society.
Hepatol Res
; 53(7): 641-648, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883289
16.
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Hepatol Res
; 53(2): 104-115, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149726
17.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306040
18.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37020416
19.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231943
20.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36103846